TRUP

TRUPANION INC

Financial Services | Mid Cap

$0.12

EPS Forecast

$341.1

Revenue Forecast

Announcing earnings for the quarter ending 2024-12-31 soon
EX-99.1 2 ex991q42019.htm EXHIBIT 99.1 Exhibit


Exhibit 99.1
trulogoenrgb2018a01.jpg

Trupanion Reports Fourth Quarter and Full Year 2019 Results

SEATTLE, WA. February 13, 2020 -- Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the fourth quarter and year ended December 31, 2019.

“Over the past two decades, we’ve delivered consistent growth while scaling our operating expenses,” said Darryl Rawlings, Founder and CEO of Trupanion. "The consistency of our growth highlights our recurring revenue, supported by industry leading retention rates, and deep competitive moats. Our moats have taken decades for us to dig and position us to benefit from the growing spotlight on our category.”

2019 Financial and Business Highlights

Total revenue was $383.9 million, an increase of 26% compared to 2018.
Total enrolled pets (including pets from our other business segment) was 646,728 at December 31, 2019, an increase of 24% over 2018.
Subscription business revenue was $321.2 million, an increase of 22% compared to 2018.
Subscription enrolled pets was 494,026 at December 31, 2019, an increase of 15% over 2018.
Net loss was $(1.8) million, or $(0.05) per basic and diluted share, compared to a net loss of $(0.9) million, or $(0.03) per basic and diluted share, in 2018.
Adjusted EBITDA was $10.6 million, compared to adjusted EBITDA of $8.6 million in 2018.
Operating cash flow was $16.2 million and free cash flow was $10.8 million in 2019. This compared to operating cash flow of $12.7 million and free cash flow of $8.3 million, which excludes the cash outflow of $52.5 million related to the third quarter 2018 purchase of our headquarters building.

Fourth Quarter 2019 Financial and Business Highlights

Total revenue was $105.5 million, an increase of 28% compared to the fourth quarter of 2018.
Subscription business revenue was $86.6 million, an increase of 22% compared to the fourth quarter of 2018.
Net income was $0.6 million, or $0.02 per basic and diluted share, compared to a net loss of $(0.3) million, or $(0.01) per basic and diluted share, in the fourth quarter of 2018.
Adjusted EBITDA was $3.7 million, compared to adjusted EBITDA of $2.5 million in the fourth quarter of 2018.
Operating cash flow was $4.5 million and free cash flow was $2.7 million for the fourth quarter of 2019. This compared to operating cash flow of $3.7 million and free cash flow of $2.6 million in the fourth quarter of 2018.











1



Revenue by Quarter

newvsexist123119supp.jpg
Conference Call
Trupanion’s management will host a conference call today to review its fourth quarter 2019 results. The call is scheduled to begin shortly after 1:30 p.m. PT/ 4:30 p.m. ET. A live webcast will be accessible through the Investor Relations section of Trupanion’s website at http://investors.trupanion.com and will be archived online for 3 months upon completion of the conference call. Participants can access the conference call by dialing 1-877-407-0784 (United States) or 1-201-689-8560 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 13698321.

About Trupanion
Trupanion is a leader in medical insurance for cats and dogs throughout the United States and Canada. For almost two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance with unlimited payouts for the life of their pets. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Omega General Insurance Company. For more information, please visit trupanion.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to, among other things, expectations, plans, prospects and financial results for Trupanion, including, but not limited to, its expectations regarding its ability to execute its business plans. These forward-looking statements are based upon the current expectations and beliefs of Trupanion’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements made in this press release are based on information available to Trupanion as of the date hereof, and Trupanion has no obligation to update these forward-looking statements.

2



In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods; the ability to keep growing our membership base and revenue; the accuracy of assumptions used in determining appropriate member acquisition expenditures; the severity and frequency of claims; the ability to maintain high retention rates; the accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency; actual claims expense exceeding estimates; regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense; the effectiveness and statutory or regulatory compliance of our Territory Partner model and of our Territory Partners, veterinarians and other third parties in recommending medical plan subscriptions to potential members; the ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals; compliance by us and those referring us members with laws and regulations that apply to our business, including the sale of a pet medical plan; the ability to maintain the security of our data; fluctuations in the Canadian currency exchange rate; the ability to protect our proprietary and member information; the ability to maintain our culture and team; the ability to maintain the requisite amount of risk-based capital; our ability to implement and maintain effective controls, including over financial reporting; the ability to protect and enforce Trupanion’s intellectual property rights; the ability to continue key contractual relationships with third parties; third-party claims including litigation and regulatory actions; the ability to recognize benefits from investments in new solutions and enhancements to Trupanion’s technology platform and website; and our ability to retain key personnel.

For a detailed discussion of these and other cautionary statements, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion’s Annual Report on Form 10-K for the year ended December 31, 2018 and any subsequently filed reports on Forms 10-Q and 8-K. All documents are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system at www.sec.gov or the Investor Relations section of Trupanion’s website at http://investors.trupanion.com.

Non-GAAP Financial Measures
Trupanion’s stated results include certain non-GAAP financial measures. These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in its industry as other companies in its industry may calculate or use non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Trupanion’s reported financial results. The presentation and utilization of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Trupanion urges its investors to review the reconciliation of its non-GAAP financial measures to the most directly comparable GAAP financial measures in its consolidated financial statements, and not to rely on any single financial or operating measure to evaluate its business. These reconciliations are included below and on Trupanion’s Investor Relations website.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, Trupanion believes that providing various non-GAAP financial measures that exclude stock-based compensation expense and depreciation and amortization expense allows for more meaningful comparisons between its operating results from period to period. Trupanion offsets sales and marketing expense with sign-up fee revenue in the calculation of net acquisition cost because it collects sign-up fee revenue from new members at the time of enrollment and considers it to be an offset to a portion of Trupanion’s sales and marketing expenses. Trupanion believes this allows it to calculate and present financial measures in a consistent manner across periods. Trupanion’s management believes that the non-GAAP financial measures and the related financial measures derived from them are important tools for financial and operational decision-making and for evaluating operating results over different periods of time.


3



Changes in Presentation of Key Operating Metrics
Trupanion presents various key operating metrics that managements uses to assess the company’s performance. Starting with the year ended December 31, 2019, Trupanion has updated its calculation of lifetime value of a pet (LVP) to include general and administrative and technology expenses, now referred to as lifetime value of a pet, including fixed expenses. This change was made in order to provide a more fulsome metric when calculating the estimated payback period for pet acquisition spend. For further discussion of the key operating metrics Trupanion uses, including a reconciliation between its historical presentation of LVP and its new presentation of lifetime value of a pet, including fixed expenses, please refer to Trupanion’s Annual Report on Form 10-K for the year ended December 31, 2019.




4



Trupanion, Inc.
Consolidated Statements of Operations
(in thousands, except share data)
 
Three Months Ended December 31,
 
Year Ended December 31,
 
2019
 
2018
 
2019
 
2018
 
(unaudited)
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Subscription business
$
86,592

 
$
70,933

 
$
321,163

 
$
263,738

Other business
18,891
 
11,707
 
62,773
 
40,218
Total revenue
105,483

 
82,640

 
383,936

 
303,956

Cost of revenue:
 
 
 
 
 
 
 
Subscription business(1)
70,718

 
57,892

 
262,139

 
215,992

Other business
17,031

 
10,543

 
56,873

 
36,598

   Total cost of revenue(2)
87,749

 
68,435

 
319,012

 
252,590

Gross profit:
 
 
 
 
 
 
 
Subscription business
15,874

 
13,041

 
59,024

 
47,746

Other business
1,860

 
1,164

 
5,900

 
3,620

Total gross profit
17,734

 
14,205

 
64,924

 
51,366

Operating expenses:
 
 
 
 
 
 
 
Technology and development(1)
2,556

 
2,487

 
10,074

 
9,248

General and administrative(1)
5,312

 
4,922

 
20,967

 
18,164

Sales and marketing(1)
9,212

 
6,994

 
35,451

 
24,999

Total operating expenses
17,080

 
14,403

 
66,492

 
52,411

Gain (loss) from investment in joint venture
(21
)
 

 
(352
)
 

Operating income (loss)
633

 
(198
)
 
(1,920
)
 
(1,045
)
Interest expense
375

 
311

 
1,349

 
1,198

Other income, net
(535
)
 
(238
)
 
(1,629
)
 
(1,309
)
Loss before income taxes
793

 
(271
)
 
(1,640
)
 
(934
)
Income tax expense (benefit)
157

 
4

 
169

 
(7
)
Net income (loss)
$
636

 
$
(275
)
 
$
(1,809
)
 
$
(927
)
 
 
 
 
 
 
 
 
Net income (loss) per share:
 
 
 
 
 
 
 
Basic
$
0.02

 
$
(0.01
)
 
$
(0.05
)
 
$
(0.03
)
Diluted
0.02

 
(0.01
)
 
(0.05
)
 
(0.03
)
Weighted average common shares outstanding:
 
 
 
 
 
 
 
Basic
34,876,438

 
33,716,975

 
34,645,345

 
31,961,192

Diluted
36,354,620

 
33,716,975

 
34,645,345

 
31,961,192

 
 
 
 
 
 
 
 
(1)Includes stock-based compensation expense as follows:
Three Months Ended December 31,
 
Year Ended December 31,
 
 
2019
 
2018
 
2019
 
2018
Cost of revenue
$
267

 
$
230

 
$
1,050

 
$
927

Technology and development
97

 
42

 
364

 
209

General and administrative
860

 
595

 
3,312

 
2,304

Sales and marketing
547

 
355

 
2,120

 
1,335

Total stock-based compensation expense
$
1,771

 
$
1,222

 
$
6,846

 
$
4,775

 
 
 
 
 
 
 
 
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:
 
Three Months Ended December 31,
 
Year Ended December 31,
 
2019
 
2018
 
2019
 
2018
Veterinary invoice expense
$
74,646

 
$
58,343

 
$
270,947

 
$
214,539

Other cost of revenue
13,103

 
10,092

 
48,065

 
38,051

     Total cost of revenue
$
87,749

 
$
68,435

 
$
319,012

 
$
252,590


5



Trupanion, Inc.
Consolidated Balance Sheets
(in thousands, except share data)
 
December 31, 2019
 
December 31, 2018
 
 
 
 
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
29,168

 
$
26,552

Short-term investments
69,732

 
54,559

Accounts and other receivables
54,408

 
31,565

Prepaid expenses and other assets
5,513

 
5,300

Total current assets
158,821

 
117,976

Restricted cash
1,400

 
1,400

Long-term investments, at fair value
4,323

 
3,554

Property and equipment, net
70,372

 
69,803

Intangible assets, net
7,731

 
8,071

Other long-term assets
14,553

 
6,706

Total assets
$
257,200

 
$
207,510

Liabilities and stockholders’ equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
4,087

 
$
2,767

Accrued liabilities and other current liabilities
13,798

 
11,347

Reserve for veterinary invoices
21,194

 
16,062

Deferred revenue
52,546

 
33,027

Total current liabilities
91,625

 
63,203

Long-term debt
26,086

 
12,862

Deferred tax liabilities
1,118

 
1,002

Other liabilities
1,611

 
1,270

Total liabilities
120,440

 
78,337

Stockholders’ equity:
 
 
 
Common stock: $0.00001 par value per share, 100,000,000 shares authorized at December 31, 2019 and December 31, 2018, 35,876,882 and 34,947,017 shares issued and outstanding at December 31, 2019; 34,781,121 and 34,025,136 shares issued and outstanding at December 31, 2018

 

Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized at December 31, 2019 and December 31, 2018, and 0 shares issued and outstanding at December 31, 2019 and December 31, 2018

 

Additional paid-in capital
232,731

 
219,838

Accumulated other comprehensive loss
250

 
(753
)
Accumulated deficit
(85,520
)
 
(83,711
)
Treasury stock, at cost: 929,865 shares at December 31, 2019 and 755,985 shares at December 31, 2018
(10,701
)
 
(6,201
)
Total stockholders’ equity
136,760

 
129,173

Total liabilities and stockholders’ equity
$
257,200

 
$
207,510


6



Trupanion, Inc.
Consolidated Statements of Cash Flows
(in thousands)
 
Three Months Ended December 31,
 
Year Ended December 31,
 
2019
 
2018
 
2019
 
2018
 
(unaudited)
 
 
 
 
Operating activities
 
 
 
 
 
 
 
Net income (loss)
$
636

 
$
(275
)
 
$
(1,809
)
 
$
(927
)
Adjustments to reconcile net loss to cash provided by operating activities:
 
 
 
 
 
 
 
Depreciation and amortization
1,274

 
1,486

 
5,632

 
4,512

Stock-based compensation expense
1,771

 
1,222

 
6,846

 
4,775

Gain on sale of equity method investment

 

 

 

Other, net
(38
)
 
(5
)
 
105

 
(240
)
Changes in operating assets and liabilities:
 
 
 
 
 
 
 
Accounts and other receivables
(4,190
)
 
344

 
(22,772
)
 
(11,248
)
Prepaid expenses and other assets
(707
)
 
(2,079
)
 
(432
)
 
(2,628
)
Accounts payable, accrued liabilities, and other liabilities
1,304

 
682

 
4,110

 
4,531

Reserve for veterinary invoices
1,872

 
1,956

 
5,059

 
3,440

Deferred revenue
2,610

 
332

 
19,418

 
10,465

Net cash provided by operating activities
4,532

 
3,663

 
16,157

 
12,680

Investing activities
 
 
 
 
 
 
 
Purchases of investment securities
(20,014
)
 
(23,295
)
 
(65,506
)
 
(52,862
)
Maturities of investment securities
21,538

 
8,008

 
49,762

 
35,413

Purchases of other investments
(4,000
)
 

 
(4,000
)
 
(3,000
)
Acquisition of lease intangibles, related to corporate real estate acquisition

 

 

 
(2,959
)
Purchases of property and equipment
(1,787
)
 
(1,080
)
 
(5,373
)
 
(56,936
)
Other
(954
)
 
(255
)
 
(2,891
)
 
(1,107
)
Net cash used in investing activities
(5,217
)
 
(16,622
)
 
(28,008
)
 
(81,451
)
Financing activities
 
 
 
 
 
 
 
Proceeds from public offering of common stock, net of offering costs

 

 

 
65,671

Proceeds from exercise of stock options
727

 
729

 
2,982

 
3,601

Shares withheld to satisfy tax withholding
(57
)
 

 
(1,667
)
 
(1,839
)
Proceeds from debt financing, net of financing fees
4,000

 
4,242

 
13,167

 
13,431

Repayment of debt financing

 

 

 
(10,000
)
Other financing

 
581

 
(438
)
 
365

Net cash provided by financing activities
4,670

 
5,552

 
14,044

 
71,229

Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net
156

 
(718
)
 
423

 
(812
)
Net change in cash, cash equivalents, and restricted cash
4,141

 
(8,125
)
 
2,616

 
1,646

Cash, cash equivalents, and restricted cash at beginning of period
26,427

 
36,077

 
27,952

 
26,306

Cash, cash equivalents, and restricted cash at end of period
$
30,568

 
$
27,952

 
$
30,568

 
$
27,952



7



The following tables set forth our key operating metrics:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Ended December 31,
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
Total Business:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total pets enrolled (at period end)
646,728

 
521,326

 
 
 
 
 
 
 
 
 
 
 
 
Subscription Business:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total subscription pets enrolled (at period end)
494,026

 
430,770

 
 
 
 
 
 
 
 
 
 
 
 
Monthly average revenue per pet
$
57.52

 
$
54.34

 
 
 
 
 
 
 
 
 
 
 
 
Lifetime value of a pet, including fixed expenses
$
523

 
$
449

 
 
 
 
 
 
 
 
 
 
 
 
Average pet acquisition cost (PAC)
$
212

 
$
164

 
 
 
 
 
 
 
 
 
 
 
 
Average monthly retention
98.58
%
 
98.60
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
Dec. 31, 2019
 
Sept. 30, 2019
 
Jun. 30, 2019
 
Mar. 31, 2019
 
Dec. 31, 2018
 
Sept. 30, 2018
 
Jun. 30, 2018
 
Mar. 31, 2018
Total Business:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total pets enrolled (at period end)
646,728

 
613,694

 
577,686

 
548,002

 
521,326

 
497,942

 
472,480

 
446,533

Subscription Business:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total subscription pets enrolled (at period end)
494,026

 
479,427

 
461,314

 
445,148

 
430,770

 
416,527

 
401,033

 
385,640

Monthly average revenue per pet
$
58.58

 
$
58.12

 
$
57.11

 
$
56.13

 
$
55.15

 
$
54.55

 
$
53.96

 
$
53.62

Lifetime value of a pet, including fixed expenses
$
523

 
$
511

 
$
482

 
$
471

 
$
449

 
$
435

 
$
431

 
$
419

Average pet acquisition cost (PAC)
$
222

 
$
208

 
$
213

 
$
205

 
$
186

 
$
155

 
$
150

 
$
165

Average monthly retention
98.58
%
 
98.59
%
 
98.57
%
 
98.58
%
 
98.60
%
 
98.61
%
 
98.64
%
 
98.63
%

8



The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands):
 
 
 
 
 
 
 
 
 
 
Three Months Ended December 31,
 
Year Ended December 31,
 
 
2019
 
2018
 
2019
 
2018
 
Net cash provided by operating activities
$
4,532

 
$
3,663

 
$
16,157

 
$
12,680

 
Purchases of property and equipment
(1,787
)
 
(1,080
)
 
(5,373
)
 
(56,936
)
 
Free cash flow
$
2,745

 
$
2,583

 
$
10,784

 
$
(44,256
)
 
Exclude building purchase, net of acquired lease intangibles

 

 

 
52,534

 
Free cash flow, excluding building purchase, net of acquired lease intangibles
$
2,745

 
$
2,583

 
$
10,784

 
$
8,278

 

9



The following tables reflect the reconciliation of acquisition cost and net acquisition cost to sales and marketing expense (in thousands):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Ended December 31,
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
Sales and marketing expenses
$
35,451

 
$
24,999

 
 
 
 
 
 
 
 
 
 
 
 
Excluding:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stock-based compensation expense
(2,120
)
 
(1,335
)
 
 
 
 
 
 
 
 
 
 
 
 
Acquisition cost
33,331

 
23,664

 
 
 
 
 
 
 
 
 
 
 
 
Net of:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sign-up fee revenue
(2,957
)
 
(2,587
)
 
 
 
 
 
 
 
 
 
 
 
 
Other business segment sales and marketing expense
(414
)
 
(377
)
 
 
 
 
 
 
 
 
 
 
 
 
Net acquisition cost
$
29,960

 
$
20,700

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
Dec. 31, 2019
 
Sept. 30, 2019
 
Jun. 30, 2019
 
Mar. 31, 2019
 
Dec. 31, 2018
 
Sept. 30, 2018
 
Jun. 30, 2018
 
Mar. 31, 2018
Sales and marketing expenses
$
9,212

 
$
9,255

 
$
8,757

 
$
8,227

 
$
6,994

 
$
6,365

 
$
5,702

 
$
5,938

Excluding:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stock-based compensation expense
(547
)
 
(577
)
 
(567
)
 
(429
)
 
(355
)
 
(358
)
 
(349
)
 
(273
)
Acquisition cost
8,665

 
8,678

 
8,190

 
7,798

 
6,639

 
6,007

 
5,353

 
5,665

Net of:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sign-up fee revenue
(730
)
 
(790
)
 
(734
)
 
(703
)
 
(655
)
 
(693
)
 
(624
)
 
(616
)
Other business segment sales and marketing expense
(152
)
 
(94
)
 
(38
)
 
(130
)
 
(102
)
 
(99
)
 
(88
)
 
(87
)
Net acquisition cost
$
7,783

 
$
7,794

 
$
7,418

 
$
6,965

 
$
5,882

 
$
5,215

 
$
4,641

 
$
4,962

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

10



The following tables reflect the reconciliation of adjusted EBITDA to net income (loss) (in thousands):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Ended December 31,
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
Net loss
$
(1,809
)
 
$
(927
)
 
 
 
 
 
 
 
 
 
 
 
 
Excluding:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stock-based compensation expense
6,846

 
4,775

 
 
 
 
 
 
 
 
 
 
 
 
Depreciation and amortization expense
5,632

 
4,512

 
 
 
 
 
 
 
 
 
 
 
 
Interest income
(1,681
)
 
(862
)
 
 
 
 
 
 
 
 
 
 
 
 
Interest expense
1,349

 
1,198

 
 
 
 
 
 
 
 
 
 
 
 
Other non-operating expenses
201

 

 
 
 
 
 
 
 
 
 
 
 
 
Income tax expense (benefit)
169

 
(7
)
 
 
 
 
 
 
 
 
 
 
 
 
Gain from equity method investment
(125
)
 
(107
)
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted EBITDA
$
10,582

 
$
8,582

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
Dec. 31, 2019
 
Sept. 30, 2019
 
Jun. 30, 2019
 
Mar. 31, 2019
 
Dec. 31, 2018
 
Sept. 30, 2018
 
Jun. 30, 2018
 
Mar. 31, 2018
Net income (loss)
$
636

 
$
782

 
$
(1,931
)
 
$
(1,296
)
 
$
(275
)
 
$
1,205

 
$
(377
)
 
$
(1,480
)
Excluding:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stock-based compensation expense
1,771

 
1,845

 
1,873

 
1,357

 
1,222

 
1,299

 
1,286

 
968

Depreciation and amortization expense
1,274

 
1,181

 
1,564

 
1,613

 
1,485

 
1,136

 
964

 
927

Interest income
(516
)
 
(411
)
 
(412
)
 
(342
)
 
(234
)
 
(317
)
 
(179
)
 
(132
)
Interest expense
375

 
340

 
317

 
317

 
311

 
336

 
332

 
219

Other non-operating expenses
(22
)
 
122

 
101

 

 

 

 

 

Income tax expense (benefit)
157

 
18

 
(46
)
 
40

 
4

 
(7
)
 
91

 
(95
)
(Gain) loss from equity method investment

 

 
(125
)
 

 

 

 
(107
)
 

Adjusted EBITDA
$
3,675

 
$
3,877

 
$
1,341

 
$
1,689

 
$
2,513

 
$
3,652

 
$
2,010

 
$
407

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 





11



Contacts:

Investors:
Laura Bainbridge, Head of Investor Relations
206.607.1929
InvestorRelations@trupanion.com

12